405
In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.
 two other patients (one after OLTX and one with Crohn's disease): Subject; two: Subject.Population; raltegravir: Treatment; 1 or 2 mg of tacrolimus twice daily.: Treatment; HIV: Treatment.Disorder; Crohn's disease: Treatment.Disorder; OLTX: Treatment.Disorder; raltegravir: Treatment.Drug; tacrolimus: Treatment.Drug; 1 or 2 mg: Treatment.Dosage; twice daily: Treatment.Freq; raltegravir: Combination.Drug; tacrolimus: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: potential therapeutic event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Treatment.Time_elapsed, Subject.Disorder, Subject.Race, Treatment.Route, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 two other patients (one after OLTX and one with Crohn's disease): Subject; two: Subject.Population; raltegravir: Treatment; 1 or 2 mg of tacrolimus twice daily.: Treatment; HIV: Treatment.Disorder; Crohn's disease: Treatment.Disorder; OLTX: Treatment.Disorder; raltegravir: Treatment.Drug; tacrolimus: Treatment.Drug; 1 or 2 mg: Treatment.Dosage; twice daily: Treatment.Freq; raltegravir: Combination.Drug; tacrolimus: Combination.Drug